Randomised Controlled Trial of an Antioxidant and Sunscreen Combination Cream for Reducing DNA Damage in Human Skin
NCT ID: NCT07301515
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
52 participants
INTERVENTIONAL
2025-03-01
2025-11-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Fifty-two healthy adults will be enrolled during the UK spring and randomized 1:1 to receive either the antioxidant-enriched SPF 50 or a matched vehicle (no SPF, no antioxidants). Participants will apply their assigned product once daily to the full face for 12 weeks under ambient ultraviolet (UV) and oxidative exposure.
Non-invasive cheek swabs collected at baseline and week 12 will be analyzed by blinded quantitative polymerase chain reaction (qPCR) to assess mtDNA integrity (ΔCt = Ct\_long - Ct\_short).
The primary objective is to determine whether the antioxidant-enriched SPF 50 reduces mtDNA damage compared with vehicle. Secondary objectives include comparing the proportion of "responders" showing reduced mtDNA damage (ΔCt \< 0) and evaluating within-participant change among habitual daily sunscreen users.
The trial aims to clarify whether adding antioxidants to high-SPF formulations can strengthen daily photoprotection by mitigating residual oxidative stress not fully blocked by UV filters alone.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This single-center, randomized, double-blind, vehicle-controlled study will evaluate the effect of a multi-antioxidant, encapsulated SPF 50 formulation on facial mitochondrial DNA integrity during twelve weeks of normal daily use. The study will be conducted during the UK spring to minimize environmental variability in ultraviolet intensity, temperature, and humidity. Healthy adults aged eighteen to seventy years with intact facial skin will be eligible regardless of baseline sunscreen habits. Individuals with active facial dermatologic disease, recent laser or peel procedures within three months, recent use of retinoids, antioxidants, or anti-inflammatory agents within four weeks, pregnancy, lactation, acute illness, or planned high-UV travel will be excluded. Participants taking medications known to affect mitochondrial function must be on stable doses for at least three months before and throughout the study.
Participants will be randomized in a one-to-one ratio to receive either an encapsulated SPF 50 plus multi-antioxidant complex or a vehicle-only cream containing no SPF and no antioxidants. A small non-randomized comparator group may continue their existing skincare routine to contextualize background variability. Study products will be visually identical, coded, and packaged in identical containers to maintain blinding of participants, investigators, and laboratory staff. Each participant will apply the assigned product once daily to the entire face at a standardized dose of approximately two milligrams per square centimeter for twelve weeks. Adherence will be encouraged through written instructions and monitored by self-report and returned product weight.
At baseline and week twelve, a defined two-by-two-centimeter cheek area will be sampled using a sterile synthetic-tipped swab. Samples will be labeled with coded identifiers and analyzed by a blinded external laboratory using a validated long- and short-amplicon quantitative polymerase chain reaction assay. The mitochondrial DNA integrity index, calculated as ΔCt = Ct\_long - Ct\_short, reflects lesion frequency, where a negative change indicates improved integrity.
The primary outcome is the change in ΔCt from baseline to week twelve between treatment arms. Secondary outcomes include the proportion of participants with ΔCt \< 0, the within-participant change among habitual daily sunscreen users compared with their prior routine, and overall safety and tolerability of both products. Efficacy analyses will include all randomized participants with valid paired baseline and week-twelve data. Between-group comparisons will be performed using two-sided parametric and non-parametric tests, and responder proportions will be compared using Fisher's exact test at a significance level of 0.05.
This study will determine whether daily application of an encapsulated SPF 50 formulation containing multiple antioxidants provides superior mitochondrial protection in facial skin compared with vehicle alone, thereby supporting the concept that antioxidant-enriched sunscreens can enhance photoprotection and reduce oxidative stress encountered in everyday life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antioxidant + Sunscreen Cream
Participants apply a daily facial cream containing encapsulated broad-spectrum UV filters (SPF 50+, PA++++) combined with an antioxidant complex composed of Phytexcell Liquorice extract (Glycyrrhiza glabra), Resveratrol bioferment, and Vitamin E (tocopherol). The cream is applied once daily in the morning to the full face for 12 weeks.
Antioxidant + Sunscreen Cream
A daily facial cream containing encapsulated broad-spectrum UV filters (SPF 50+, PA++++) combined with an antioxidant complex composed of Phytexcell Liquorice extract (Glycyrrhiza glabra), Resveratrol bioferment, and Vitamin E (tocopherol). The cream is applied once daily in the morning to the full face (approximately 2 mg/cm²) for 12 weeks.
Vehicle-Only Cream
Participants apply an identical-appearing vehicle cream without UV filters, or antioxidants. The product base, texture, and packaging are identical to the active formulation. It is applied once daily in the morning to the full face for 12 weeks.
Placebo cream
An identical-appearing vehicle cream without UV filters or antioxidant actives. The base formulation, texture, and packaging are identical to the active product. Applied once daily in the morning to the full face (approximately 2 mg/cm²) for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Antioxidant + Sunscreen Cream
A daily facial cream containing encapsulated broad-spectrum UV filters (SPF 50+, PA++++) combined with an antioxidant complex composed of Phytexcell Liquorice extract (Glycyrrhiza glabra), Resveratrol bioferment, and Vitamin E (tocopherol). The cream is applied once daily in the morning to the full face (approximately 2 mg/cm²) for 12 weeks.
Placebo cream
An identical-appearing vehicle cream without UV filters or antioxidant actives. The base formulation, texture, and packaging are identical to the active product. Applied once daily in the morning to the full face (approximately 2 mg/cm²) for 12 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy facial skin with no active dermatologic disease
* Willing to apply the assigned product daily for 12 weeks
* Willing to avoid additional facial skincare products during the study period
* Able to attend baseline and week-12 visits for cheek-swab collection
* Willing to maintain stable medication and supplement use throughout the study
* Provided written informed consent
Exclusion Criteria
* Laser, peel, or energy-based facial treatment within the past 3 months
* Use of topical/systemic retinoids, antioxidants, or anti-inflammatory agents within 4 weeks of baseline
* Pregnancy or breastfeeding
* Recent acute illness or infection
* Planned travel to high-UV or sunny destinations during the study period
* Current smoker or regular e-cigarette user
* Participation in another clinical trial within the previous 30 days
* Known allergy or sensitivity to study-product ingredients
* Unstable medical conditions or medications known to affect mitochondrial function (e.g., recent changes in antibiotics, statins, or thyroid medication)
18 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guy's and St Thomas' NHS Foundation Trust
OTHER
Newcastle-upon-Tyne Hospitals NHS Trust
OTHER
Skin Analytics Limited
INDUSTRY
Klira Skin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emma Craythorne, Medicine MBChB
Role: PRINCIPAL_INVESTIGATOR
Guy's and St Thomas' NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St John's Institute of Dermatology
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KLR-MITO-2025-01
Identifier Type: -
Identifier Source: org_study_id